Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365346 | 0.90 | GRIN2B (0.49) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2226508 | 0.88 | FAAH (0.47) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2228311 | 0.86 | FAAH (0.44) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2228770 | 0.85 | GRIN2B (0.43) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2226276 | 0.85 | TEAD1 (0.53) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2365329 | 0.85 | FAAH (0.50) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2229709 | 0.84 | LMNA (0.48) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2228972 | 0.83 | GRIN2B (0.43) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2229065 | 0.83 | PTGDR2 (0.40) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL2229233 | 0.83 | GRIN2B (0.53) | GRIN2BFAAHCYP2D6CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803258-B | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SAI NUOFEI (FR) | 2016-04-20 | — | — | CN | claimed |
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | claimed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | claimed |
| CN-102803258-A | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SANOFI AVENTIS | 2012-11-28 | — | — | CN | claimed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | claimed |
| WO-2011089550-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2011-07-28 | — | — | WO | claimed |
| CN-105837565-A | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | 赛诺菲 | 2016-08-10 | — | — | CN | disclosed |
| CN-102803258-B | Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use | SAI NUOFEI (FR) | 2016-04-20 | — | — | CN | disclosed |
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | disclosed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | disclosed |
| WO-2011089550-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | PRMT9, PRMT8, CBR1 | GRIN2B 362/4885FAAH 1562/4885CYP2D6 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.